Everest trades at 0.97x book and 11x earnings while the soft cycle bites and casualty reserves leak. The price already discounts pain; bull case requires only that 2024-2025 adverse development is finite.

Plain English

Everest is a Bermuda company that sells insurance to other insurance companies. When a hurricane wipes out a town, your local insurer pays you and Everest pays your local insurer. Everest collects premiums today and pays losses years later, holding the cash in between and earning interest on it. The business is predictable in shape but very lumpy in timing. Right now too many companies are competing for the same business, so prices are dropping. The stock costs about $354 and the company's net worth per share is about $366 — you are buying assets for less than they are worth. The risk is the worth itself is an estimate.

Thesis

Everest Group is a top-five global reinsurer plus a mid-tier specialty primary insurer, domiciled in Bermuda for tax efficiency. Its earnings come from two compounding engines: (1) underwriting profit on roughly $16B of annual premium and (2) net investment income on a $46B float-and-capital portfolio. In a hard market this is a genuinely good business; in a soft market with reserve drift it is mediocre. We are entering a soft market with reserve drift.

The scorecard composite is 67/100, a perfectly average grade dragged down by a profitability score of 11/30 (10-yr ROIC averages to 0.0% in the model because GAAP operating income is dominated by reserve and investment noise) and lifted by a valuation score of 23/30. Reverse-DCF implies the market expects -4.3% growth in perpetuity, and the IV range of $412 - $1,031 (base $691) puts the current $353.57 price at a 0.51x P/IV ratio.

The math works without heroics. Tangible book is roughly $366/share. If Everest earns a normalized through-cycle 10% ROE on book ($37/share) and the market accepts a 1.0x book multiple (the long-run reinsurer mean is closer to 1.1-1.2x), you compound at 10% from a starting point that already includes a free 50%+ rerating. TTM owner earnings of $1.436B against a $14.8B market cap is a 9.7% earnings yield. End math: pay $0.51 for $1.00 of base IV, with a hard floor at book. Margin of safety is wide, but the asset is reserves-dependent and reserves are estimates [3].

Moat

Reinsurance is a commodity industry with a single durable cost advantage: the cost of float. Buffett laid out the framework in 1999 — "the key determinants are: (1) the amount of float the business generates; (2) its cost; and (3) most critical of all, the long-term outlook for both of these factors" [3]. Everest sits in a structurally weaker position than Berkshire's reinsurance operations on each axis, but it is not without competitive standing.

Pricing power — limited and cyclical. Reinsurance pricing is set quarterly at renewal and is dominated by global capital supply. In 2025 Berkshire itself observed that "the reinsurance sector has attracted significant increases in available capital from both the traditional and alternative markets...has led to significant price declines in property reinsurance. In most casualty reinsurance segments, claims inflation continued to outpace pricing" [3]. Everest takes the same pricing the Berkshire reinsurance team takes — they just lack the discipline to walk away. Verdict: NONE.

Switching costs — modest. Cedents value continuity (the same reinsurer covering the same layer for many years) but every contract reprices annually. Switching costs are real but small.

Network effects — none in any meaningful sense.

Intangibles — a real but narrow asset. Everest has an A+ AM Best rating, multi-decade broker relationships at Aon, Guy Carpenter and Marsh, and a Lloyd's syndicate (Syndicate 2786). Cedents will not hand a multi-million-dollar excess layer to an unrated startup, so there is a real barrier to entry — but it is wide, not high. Roughly 25 reinsurers globally clear the rating bar.

Cost advantages — this is the only place Everest can claim something durable. Bermuda domicile is the centerpiece: until 2025 the holding company paid effectively no income tax. The 15% Bermuda corporate income tax effective 2025 narrows that gap meaningfully. Outside of tax, scale gives Everest a low expense ratio (mid-20s combined with a ~70% loss ratio in good years), and the capital base is large enough to write large unique risks that smaller carriers cannot. But Berkshire's reinsurance operation enjoys all the same advantages plus a permanent capital base and no quarterly earnings pressure — "we give our insurance managers autonomy to run their businesses, without quarterly earnings targets or growth mandates that might otherwise distort their underwriting judgment" [3]. Everest's stock-incentivized management does not have that luxury.

Competitor stress test ($10B + 5 years). A new entrant with $10B of capital can be A-rated within 18 months and writing meaningful business within three years. The 2005-2006 "class of 2005" Bermuda startups (Validus, Flagstone, Lancashire) demonstrated this. Capital is the only barrier and capital is fungible. Erosion is continuous, not a question of if.

Reserve fragility caveat. The Buffett 1984 letter is the relevant warning: "the corpse is supposed to file the death certificate" [from canon - failures section]. Reinsurer book value is whatever management says it is, plus or minus 10-15% in the casualty lines. Everest had to take material adverse development in 2023 and again in 2024 on US casualty business — the kind of revision that, per Buffett, "made a mockery of the earnings that investors had relied on earlier" [Buffett 1999, canon].

The moat is the cost-advantage of Bermuda tax + scale + rating, partially eroded by the new global minimum tax and continuously eroded by alternative capital. It is real but narrow.

Moat verdict: NARROW.

Management

Capital allocation at Everest under CEO Juan Andrade (since 2020) and CFO Mark Kociancic has been adequate but not exceptional. The five capital choices:

1. Reinvest in the business. Everest grew gross written premium roughly 10-12% per year during the 2021-2023 hard market, taking share when pricing was attractive. This is the right move and they did it competently. In 2025 they appear to be slowing growth (premiums earned in Q3 2025 were $3.86B vs $3.92B Q3 2024), which is appropriate as pricing softens. Grade on this axis: B+. The concern is that the 2021-2023 vintage written at peak rates is now showing adverse development on the casualty side, which suggests the underwriting was less disciplined than the volume optics implied.

2. Acquisitions. Everest has not made meaningful acquisitions in the recent past. Specialty reinsurers that have tried to acquire (RenaissanceRe / Validus, AXIS / Novae) have generally destroyed value. Restraint here is wise. Grade: B.

3. Debt. Conservatively financed. Long-term debt is a small fraction of equity. Interest coverage is comfortable. The scorecard cannot compute net-debt-to-EBITDA for an insurer (the metric is not meaningful), but the balance sheet is sound. Grade: A.

4. Buybacks. This is where management deserves both credit and scrutiny. Treasury shares grew from 31.3M (Dec 2024) to 32.5M (Sept 2025) — roughly $400M repurchased in nine months. Share count has crept up 16% over the past 10 years (1.1605x per the scorecard), so historical buybacks have not even kept pace with stock-based compensation issuance — that is bad. The current pace, at a price below book, is value-accretive: every share retired at $353 increases per-share book value of $366. But the right answer at half of IV would be a Henry Singleton-style aggressive buyback financed by issuing reinsurance-linked debt or simply running off excess capital. Management is buying steadily but not opportunistically. Grade: B-.

5. Dividends. Everest pays a stable, growing dividend of roughly $8/share annualized — about a 2.3% yield. For a reinsurer this is appropriate; insurance company dividends signal capital adequacy and are a key part of total return for the shareholder base. Grade: B+.

Communication quality. The 10-K and 10-Q are dense, technical, and follow industry conventions but lack the candor of a Buffett letter. The forward-looking risk-factor list (catastrophe exposure, social inflation, adverse development, pricing decreases, reinsurance recoverability) is comprehensive and honest [from 10-Q], but the MD&A frames adverse development as one-off rather than as evidence of underwriting discipline lapses. This is normal for the industry but does not earn an upgrade.

Reserve practice. This is the dispositive variable. Everest took multiple unfavorable prior-year reserve adjustments in the past two years on US casualty lines. Buffett warned in 1984: "insurers have enormous latitude in figuring their underwriting results...the consequences of these miscalculations flow directly into earnings" [canon]. Everest's ratio of reserves to premium is in line with peers and the auditors have signed off, but adverse development is a tell. We do not know if 2024-2025 was the cleanup or the first salvo.

Per-share economic value over a decade. Book value per share has compounded at roughly 8-10% over the past decade including dividends. That is a respectable but not outstanding result for a financial firm using ~3:1 leverage on a low-cost float base.

Capital allocator: B.

Industry

Property and casualty reinsurance, viewed through Porter's Five Forces:

Threat of new entrants — HIGH. Reinsurance is the most capital-elastic industry in finance. After every major catastrophe (Andrew 1992, KRW 2005, Sandy 2012) a new wave of capital arrives in Bermuda within 12-18 months, takes share at the top of the cycle, and erodes returns for incumbents. Insurance-linked securities (ILS), catastrophe bonds, sidecars, and pension fund capital have permanently lowered the barriers. The market today has more reinsurance capital relative to premium than at almost any point in history. Berkshire's 2025 letter frames it directly: "the reinsurance sector has attracted significant increases in available capital from both the traditional and alternative markets...has led to significant price declines in property reinsurance" [3].

Bargaining power of buyers (cedents) — MEDIUM-HIGH. Cedents are large, sophisticated primary insurers (Travelers, Allianz, Munich Re's primary arm, AIG) who place reinsurance through three brokers (Aon, Marsh/Guy Carpenter, WTW). Three brokers controlling the flow gives cedents leverage and forces standardization of terms. In hard markets buyer power is weaker; in soft markets it is brutal. We are entering soft.

Bargaining power of suppliers — LOW. The "suppliers" to a reinsurer are capital providers (equity and debt holders) and talent. Capital is plentiful. Underwriting talent is expensive but mobile.

Threat of substitutes — HIGH and rising. Cat bonds, sidecars, ILS funds, parametric covers, and direct capital markets transactions substitute for traditional reinsurance every year. Berkshire's letter explicitly identifies "alternative markets" as part of the capital glut [3]. For property cat the substitute is now mature; for casualty it is emerging.

Competitive rivalry — HIGH. Roughly 25 globally rated reinsurers compete on price for the same renewals at the same broker desks. Munich Re, Swiss Re, Hannover Re, SCOR, RenaissanceRe, Berkshire, and the Bermuda specialists all bid on overlapping treaties. Differentiation is rating, capacity, and relationship — not product.

Value pool location. The economic profit pool in P&C reinsurance has been pushing back toward primary insurers and toward alternative capital structures for two decades. Reinsurers earn money in spikes (post-loss hard markets) and give it back in troughs. Long-run aggregate ROE for the industry is roughly 8-10% — at or below cost of equity. This is why the canon framework for thinking about reinsurance is float economics rather than franchise economics: you only own a reinsurer if either (a) the cost of float is genuinely negative through cycles or (b) you are buying assets at a meaningful discount to a defensible book value.

Everest case (b) is intact today. The price-to-book is below 1.0x and the price-to-base-IV is 0.51x. But this is the opposite of a wonderful business at a fair price; it is a fair business at a wonderful price.

Industry Verdict: Average.

Inversion

Bear case. Steel-manning the short.

The single event that kills this thesis. A meaningful adverse loss reserve development charge in 2026 or 2027 — say $1.5-2.5B pre-tax — on the 2018-2022 US casualty vintages. The 2025 9-month combined ratio is already running at roughly 96-97% (loss ratio 70.1% from $8.2B losses on $11.7B premiums earned, plus ~22% commission and 6.4% other underwriting, plus corporate). A $2B reserve charge would push the combined ratio to ~115%+ for a year and wipe out roughly 14% of book value. At a price-to-book that re-rates to 0.7x in panic, the stock is $190. This is not theoretical: AIG, Travelers, and several Lloyd's syndicates have taken charges of this magnitude on identical book vintages.

Why the moat is narrower than bulls think. The bull narrative leans on Bermuda tax efficiency, A+ rating, and broker relationships. All three are deteriorating. Bermuda's 15% corporate income tax took effect January 1, 2025, eliminating most of the structural tax advantage. The A+ rating is shared by 24 other reinsurers — it gates access but does not create pricing power. Broker relationships are at three firms that are explicitly trying to commoditize the placement process via algorithmic placement and ILS substitution. The moat sources are all partially or wholly eroding simultaneously.

Why management is worse than it appears. The 16% increase in share count over 10 years tells the story. Management has been issuing more equity through stock comp than they have repurchased in net terms over the cycle. Buybacks at $200-$400 per share over the past five years have been steady but not opportunistic — they were buying nearly the same dollars at $400 that they are buying at $350. A truly value-conscious allocator at half of IV would be returning excess capital aggressively. Andrade and Kociancic are competent operators, not capital allocators in the Singleton mold. The compensation package incentivizes book-value growth over per-share economics, and you can see the result in the share count drift.

What bulls are extrapolating that won't hold. Bulls extrapolate (1) the 2021-2023 hard-market combined ratio of ~88-90%, (2) the elevated investment yield from higher rates, and (3) the post-pandemic reserve discipline. None of the three are durable. The hard market is over — Berkshire's letter says so plainly [3]. Reinvestment yields are stable but not rising — so future investment income is what it is. And reserve discipline is exactly what is now being tested by 2024-2025 charges. The forward earnings power of EG is closer to a 92-94% combined ratio, $1.5B of net investment income on $46B of investments yielding ~3.5%, and a normalized ROE of 9-11% — which on $15.4B of equity is $1.4-1.7B of earnings. That is what TTM owner earnings already show. There is no upside surprise embedded.

Valuation trap (multiple compression / regime change). The bull says Everest should trade at 1.2x book once the cycle turns. The bear says the cycle is structurally flatter, the Bermuda tax advantage is gone, and 1.0x book is the new ceiling. If forward ROE compresses to 8% (the long-run industry average) and the multiple compresses to 0.85x book in a soft market, the stock is worth ~$311 — below today's price. The IV range in the scorecard ($412-$1,031) assumes mean-reversion of ROE to a level that may not return. The reverse-DCF says the market expects -4.3% growth in perpetuity; that is not unreasonable as a base case for a reinsurer with shrinking real return on capital.

The compounding regime change. For 30 years, the implicit deal in P&C reinsurance was: tolerate cycle volatility, capture pricing in hard markets, compound book value at low double digits. The deal has changed. ILS capital now stays in the market through the cycle; cat bonds price faster than treaty reinsurers can re-rate; AI-augmented brokers can place fronted programs in days. Everest is not a leader in any of these adjacent capabilities. The risk is not that EG goes to zero; it is that EG is dead money for a decade while the industry goes through a structural reset, with its returns compressing toward the cost of equity and its book value compounding at 4-6% rather than 9-10%.

If I am right, the stock could be worth $250-$300 within 2-3 years (and roughly flat over 5).

Lollapalooza Bias Check

Active biases in the analyst right now:

Anchoring. The single largest bias on this name is anchoring to the IV midpoint of $691 vs the current price of $354. The 2:1 ratio creates a near-irresistible pull toward "this is obviously cheap." But IV is computed off a normalized owner-earnings figure that itself depends on through-cycle assumptions for combined ratio and investment yield. If through-cycle ROE is 8% rather than 11%, the IV is roughly $500, not $691. The anchor is doing a lot of work and I should consciously discount it.

Recency bias in the opposite direction. Two years of adverse reserve development have made me more cautious than I would be if I were looking only at the 10-year average book-value compounding. There is a temptation to over-weight the last eight quarters of pain.

Authority / social proof. Berkshire's 2025 letter — repeatedly cited above [3] — describes the reinsurance environment in pessimistic terms. Buffett is the most authoritative voice in the industry, and his pessimism makes me more pessimistic. This is reasonable insofar as he has more information than I do, but I should be aware that I am borrowing his conviction rather than building it independently. Berkshire walks away from soft markets because they have alternatives; Everest cannot walk away because reinsurance is their entire business. The same market may rationally produce different reactions.

Confirmation bias. Once you frame a reinsurer as "book × ROE > DCF," you start looking for evidence that book is the floor. I am underweighting the evidence that book itself can move — adverse development directly reduces book; AOCI swings on the bond portfolio can move book by 5-10% in a quarter; foreign currency translation moves it.

Incentive caution (Munger's most important bias). Management's incentive comp is tied to growth in book value per share. That creates a structural incentive to (a) under-reserve, (b) write at the margin in soft markets to preserve volume, and (c) prefer dividends and modest buybacks over aggressive capital return. None of these are fraud — they are just how the comp plan steers behavior. I should assume management acts in line with the comp plan.

Deprival super-reaction. The stock at 0.51x P/IV creates an intense feeling that I will miss something obvious if I do not act. This is the opposite of analytical clarity. Most stocks at 0.5x reported IV deserve to be there.

Net effect: anchoring + deprival super-reaction push toward Buy; recency + authority + incentive caution push toward Hold. The synthesis is to size cautiously, not to swing.

10-Year Outlook

In ten years, will Everest still write reinsurance and specialty insurance? Almost certainly yes. The Bermuda + Lloyd's structure is durable; the broker channels are durable; the customer base of large primary insurers is durable. The fundamental shape of the business will be the same.

Will the customer base be larger? Modestly. Global insurance penetration grows roughly with nominal GDP — call it 4-5% per year in developed markets, faster in emerging. Reinsurance ceded ratio is structural and roughly flat. So gross written premium can grow 4-6% per year in real terms over a decade. At 5% per year, $16B of premium becomes ~$26B.

Will profit per customer be higher? Probably not. Combined ratios are structurally moving from the high 80s in hard markets toward the mid-90s, with shorter cycle peaks. ILS substitution is a one-way ratchet on property cat margins. Casualty margins depend on social inflation, which is trending unfavorably. The base case is flat to modestly down per-unit profitability.

Will the moat be wider? No. The Bermuda tax advantage narrowed in 2025; alternative capital is structurally cheaper than it was a decade ago; brokers are commoditizing placement. The moat trajectory is mildly negative.

The single biggest threat. Not catastrophe — the industry handles those. The biggest threat is the structural transition to a flatter, ILS-dominated reinsurance market in which traditional balance-sheet reinsurers earn cost-of-capital returns through the cycle. In that world, EG is worth roughly book value, growing at 5-7% per year, with a 2-3% dividend. Total return ~7-10% — fine, not great.

This is where the price discount earns its keep. Buying at 0.51x base IV gives a meaningful margin against the bear scenario. If through-cycle ROE compresses to 8% and the multiple is 0.85x book, you still earn high single-digits from the entry price.

The analyst's confidence in the direction of the next ten years is reasonable; the confidence in the magnitude of returns is moderate. The reserve question is the swing variable.

CONFIDENCE: medium

Position Guidance

• Recommendation: Buy
• Conviction: medium
• Target buy price: $360 (at or below current tangible book value per share of ~$366; meaningful margin of safety begins here)
• Target trim price: $700 (just above the IV base of $691; bull-case IV $1,031)
• Position sizing: 2-3% portfolio weight. Half-position now at $354; add a half-position only if (a) price falls below $300 OR (b) Q4 2025 / Q1 2026 reserve disclosure confirms no further adverse development on the 2018-2022 casualty vintages.
• Holding period: 3-5 years; this is a mean-reversion + dividend-and-buyback compounder, not a forever holding.
• Stop conditions: sell if (a) cumulative adverse reserve development in 2026 exceeds $1.5B, (b) AM Best downgrades to A or below, or (c) management makes a meaningful acquisition at a premium to book.